The nephrotoxicity of bortezomib: did we miss a complication after 20 years of use and multiple landmark trials?

Nephrol Dial Transplant. 2023 Sep 29;38(10):2099-2104. doi: 10.1093/ndt/gfad061.

Authors

Raad B Chowdhury¹, Efstathios Kastritis², S Vincent Rajkumar³, Nelson Leung^{1

3}

Affiliations

¹ Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
² Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
³ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

PMID: 37002539
DOI: 10.1093/ndt/gfad061

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Bortezomib / adverse effects
Drug-Related Side Effects and Adverse Reactions*
Humans
Multiple Myeloma*
Renal Insufficiency*

Substances

Bortezomib
Antineoplastic Agents